Ronald E. Blaylock, a director at Pfizer Inc. (NYSE:PFE), purchased 19,457 shares of the company's common stock. The transaction was valued at a total of $499,072, with each share priced at $25.65.
NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with $63.6 billion in annual revenue and an impressive 74% gross profit margin, has announced the U.S. Food and Drug Administration's ...
Patients with BRAF V600E-mutated metastatic colorectal cancer experienced improved responses when treated with Braftovi plus Erbitux and mFOLFOX6.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback